白蛋白治疗肝硬化合并非SBP感染的随机试验
多中心开放标签随机试验纳入118例肝硬化合并非自发性细菌性腹膜炎(SBP)感染且存在不良结局风险因素的患者,比较抗生素联合白蛋白(研究组61例)与单用抗生素(对照组57例)。主要结局院内死亡率两组无显著差异(研究组13.1% vs 对照组10.5%,P=.66);研究组基线ACLF合并肾功能不全比例更高(44.3% vs 24.6%,P=.02),但ACLF缓解比例更高(82.3% vs 33.3%,P=.03),院内感染发生率更低(6.6% vs 24.6%,P=.007)。
要点
- 肝硬化合并非SBP感染患者加用白蛋白未显著降低院内死亡率(13.1% vs 10.5%,P=.66)。
- 研究组基线ACLF合并肾功能不全比例显著更高(44.3% vs 24.6%,P=.02)。
- 研究组ACLF缓解比例更高(82.3% vs 33.3%,P=.03),院内感染更少(6.6% vs 24.6%,P=.007)。
核心结论
- 在晚期肝硬化合并非SBP感染的随机试验中,白蛋白联合抗生素组与单用抗生素组院内死亡率相似(研究组13.1% vs 对照组10.5%,P=.66)。
- 接受白蛋白的患者基线病情更重,但随访期间ACLF缓解比例更高、院内感染比例更低。
研究设计与样本
- 多中心、开放标签随机试验,纳入118例肝硬化合并非SBP感染且存在不良结局额外风险因素的患者。
- 患者随机接受抗生素联合白蛋白(研究组,n=61)或单用抗生素(对照组,n=57)。
- 主要结局为院内死亡率,次要结局为白蛋白对病程的影响。
主要发现
- 基线时两组标准实验室检查、炎症血清标志物、循环功能障碍及肝病严重程度评分无显著差异。
- 研究组ACLF合并肾功能不全的合并患病率显著高于对照组(44.3% vs 24.6%,P=.02),提示研究组基线总体严重程度更高。
- 主要结局院内死亡率两组无显著差异(研究组13.1% vs 对照组10.5%,P=.66)。
- 仅研究组循环和肾功能改善;研究组ACLF缓解比例显著更高(82.3% vs 对照组33.3%,P=.03)。
- 研究组发生院内感染的比例显著更低(6.6% vs 对照组24.6%,P=.007)。
临床怎么用
- 对于肝硬化合并非SBP感染且存在不良结局风险因素的患者,加用白蛋白未显示降低院内死亡率。
- 研究组基线ACLF合并肾功能不全比例更高,但ACLF缓解比例更高、院内感染比例更低。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We performed a randomized trial to determine whether albumin should be administered to patients with infections unrelated to spontaneous bacterial peritonitis (SBP). METHODS: We performed a multicenter, open-label trial in which 118 patients with cirrhosis, non-SBP infections, and additional risk factors for poor outcome were randomly assigned to receive antibiotics plus albumin (study group; n = 61) or antibiotics alone (control group; n = 57). The primary outcome was in-hospital mortality; secondary outcomes were effect of albumin on disease course. RESULTS: There were no significant differences at baseline between groups in results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores. However, the combined prevalence of acute on chronic liver failure (ACLF) and kidney dysfunction was significantly higher in the study group (44.3% vs 24.6% in the control group; P = .02), indicating greater baseline overall severity. There was no significant difference in the primary outcome between groups (13.1% in the study group vs 10.5% in the control group; P = .66). Circulatory and renal functions improved in only the study group. A significantly higher proportion of patients in the study group had resolution of ACLF (82.3% vs 33.3% in the control group; P = .03). A significantly lower proportion of patients in the study group developed nosocomial infections (6.6% vs 24.6% in the control group; P = .007). CONCLUSIONS: In a randomized trial of patients with advanced cirrhosis and non-SBP infections, in-hospital mortality was similar between those who received albumin plus antibiotics vs those who received only antibiotics (controls). However, patients given albumin were sicker at baseline and, during the follow-up period, a higher proportion had ACLF resolution and a lower proportion had nosocomial infections. ClinicalTrials.gov no: NCT02034279.
引用
- Fernández J, Angeli P, Trebicka J, et al. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol. 2019. PMID: 31394283. doi:10.1016/j.cgh.2019.07.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。